Bisphosphonates are the leading drugs for the treatment of osteoporosis. In randomized
controlled trials (RCTs), alendronate, risedronate, and zoledronate have shown to reduce …

Background Given the limited availability of healthcare resources and the recent introduction
of new anti-osteoporosis drugs, the interest in the cost effectiveness of drugs in …

Hip fracture incidence rates in Austria over a period of 20 years (1989–2008) were
assessed. Age-standardized incidence rates increased until 2005 but decreased thereafter …

The competitive price of generic bisphosphonates has had a marked effect on practice
guidelines, but an increasing body of evidence suggests that they have more limited …

We evaluated the differences in persistence with weekly oral bisphosphonate therapy
according to the initial drug. Persistence to weekly oral preparations remains suboptimal …

METHODS: Since many papers have been recently published and new formulations or
dosages have been developed, our aim was to review the most significant medical literature …

Osteoporosis, especially in postmenopausal women, has a high socioeconomic impact on
the individual and on the society. There are several drugs for its prevention and treatment; …

Age is one of the principal risk factors for development of frailty fractures. Age pyramids
show a population that is becoming increasingly more elderly, with an increasing incidence …

A osteoporose, principalmente na pós-menopausa, apresenta alto impacto socioeconômico
para o indivíduo e para a sociedade. Existem vários medicamentos para sua prevenção e …

Background and aims: This evaluation of the cost-effectiveness of risedronate vs generic
alendronate is based on effectiveness data from a large real practice study. Applying a …